Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

Pignata S;Scambia G;Ferrandina G;Savarese A;Sorio R;Breda E;Gebbia V;Musso P;Frigerio L;Del Medico P;Lombardi AV;Febbraro A;Scollo P;Ferro A;Tamberi S;Brandes A;Ravaioli A;Valerio MR;Aitini E;Natale D;Scaltriti L;Greggi S;Pisano C;Lorusso D;Salutari V;Legge F;Di Maio M;Morabito A;Gallo C;Perrone F

2011-01-01